From out of the mists of confusion created by the European Medicines Agency’s initial ineptitude in seeking a new head – its first job adver...

Will it matter if Europe’s top medicines regulator, the European Medicines Agency (EMA), is without an Executive Director for the next six m...

The European regulatory agency, EMEA, and Europe's various cost-effectiveness watchdogs are brushing up a little too close for comfort, ...

In a bid to resurrect investors'--and perhaps potential European partners'--interest in its beleaguered COPD drug aclidinium (brande...

We heard a phrase we haven't heard in a long time this week: "Drug Lag." Merck EVP Worldwide Regulatory Affairs & Product ...

As the European Commission today gave its final green light to Novo’s much-anticipated GLP-1 inhibitor liraglutide ( Victoza ) (no surprise...

“EMEA is not the FDA of Europe, and the FDA is not the EMEA of the United States.” That’s how Richard Pazdur – the head of FDA’s Office of O...

It’s all smiles again at Novo Nordisk following yesterday’s news that EMEA has recommended approval of its GLP-1 agonist liraglutide ( Vict...